Relypsa, Sanofi in starting gate for patiromer launch, with FDA decision imminent

Relypsa ($RLYP) and Sanofi ($SNY) are raring to go for a prospective launch of patiromer, a treatment for hyperkalemia. And they need to get going, considering a competitor med might hit the market in mid-2016. All they need is an FDA approval, and that yea-or-nay decision is expected today. More from FiercePharmaMarketing

Suggested Articles

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.